By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute’s TGen Drug Development (TD2) arm will use Horizon Discovery’s isogenic cell lines in a partnership focused on developing pharmacogenomic tools for use in cancer drug research services, TGen said today.

The partners will use Horizon Discovery Services’ panel of more than 200 genetically-defined X-Man human isogenic cell lines in TD2’s comprehensive pre-clinical service before it conducts certain in-house clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.